I have enough high-quality content for a full 10-mark exam answer. Let me compose it now.
ED95 of Neuromuscular Blocking Drugs
Model Answer - MD Anaesthesia (10 Marks)
1. Definition (2 marks)
ED95 stands for the Effective Dose that produces 95% depression of maximal muscle twitch response in 50% of patients studied under defined anesthetic conditions.
It is important to understand the precise terminology here, as it differs from the conventional pharmacological use of "ED95":
- In conventional pharmacology, ED95 means the dose effective in 95% of the population.
- In neuromuscular pharmacology, ED95 = the median dose (effective in 50% of patients) required to produce 95% depression of the single twitch response (measured at the adductor pollicis muscle using ulnar nerve stimulation).
This is derived from a dose-response (quantal) curve - a sigmoid curve plotting cumulative percentage of patients against dose. The ED95 is read off at the 95% twitch-suppression point on this curve.
Barash Clinical Anesthesia, 9e, p. 1604
2. How ED95 Expresses Potency (1 mark)
ED95 is the standard measure of potency of neuromuscular blocking drugs (NMBDs). A lower ED95 = more potent drug (smaller dose needed for effect). A higher ED95 = less potent drug.
Potency and onset are inversely related (see below).
3. ED95 Values of Clinically Used NMBDs (2 marks)
| Drug | Class | Duration | ED95 (mg/kg) | Intubating Dose (2× ED95) |
|---|
| Succinylcholine | Depolarizing | Ultra-short | 0.3 mg/kg* | 1.0-1.5 mg/kg |
| Rocuronium | Aminosteroid | Intermediate | 0.3 mg/kg | 0.6 mg/kg |
| Vecuronium | Aminosteroid | Intermediate | 0.05 mg/kg | 0.1 mg/kg |
| Cisatracurium | Benzylisoquinolinium | Intermediate | 0.05 mg/kg | 0.1-0.15 mg/kg |
| Atracurium | Benzylisoquinolinium | Intermediate | 0.23 mg/kg | 0.5 mg/kg |
| Pancuronium | Aminosteroid | Long | 0.07 mg/kg | 0.1 mg/kg |
| Mivacurium | Benzylisoquinolinium | Short | 0.08 mg/kg | 0.15-0.2 mg/kg |
*Succinylcholine ED95 by cumulative dose-response methods is actually <0.3 mg/kg; the conventional dose of 1 mg/kg = ~3× ED95.
Key fact: The four most commonly used NMBDs in current practice have an ED95 of either 0.3 mg/kg (succinylcholine, rocuronium) or 0.05 mg/kg (cisatracurium, vecuronium).
Barash Clinical Anesthesia, 9e, p. 1597; Miller's Anesthesia, 10e, p. 3229
4. Clinical Significance of ED95: Intubating Dose (1 mark)
The standard intubating dose = 2× ED95. This provides:
- Complete neuromuscular blockade in the vast majority of patients
- Acceptable onset time
- Reliable intubating conditions
If the trachea has already been intubated (e.g., with succinylcholine) and an NMBD is needed only for surgical relaxation, a dose slightly less than the ED95 is often sufficient for most surgical settings.
| Clinical Purpose | Dose Used |
|---|
| Surgical relaxation only | ~0.5-1 × ED95 |
| Standard tracheal intubation | 2 × ED95 |
| Rapid sequence intubation (rocuronium) | 3-4 × ED95 (0.9-1.2 mg/kg) |
Miller's Anesthesia, 10e, p. 3269
5. Inverse Potency-Onset Relationship (2 marks)
This is a high-yield concept for exam purposes.
The less potent the NMBD, the faster its onset of action (at equipotent doses).
Mechanism:
- At equipotent (2× ED95) doses, a less potent drug requires more molecules to achieve the same effect
- More molecules = higher molar concentration delivered to the neuromuscular junction
- Higher concentration gradient across the NMJ = faster diffusion and faster receptor occupancy
- Therefore, onset is faster
Rocuronium (ED95 = 0.3 mg/kg, molar ED95 = 0.54 μM/kg) has approximately:
- 13% the molar potency of vecuronium
- 9% the molar potency of cisatracurium
This explains why rocuronium at 1.2 mg/kg (4× ED95) achieves intubating conditions within 60 seconds, comparable to succinylcholine - by giving a very large number of molecules.
Mathematically: Onset time ∝ 1/Molar potency (i.e., onset time decreases as ED50 or ED95 increases)
This relationship holds for most steroidal NMBDs (exception: atracurium does not follow this rule).
Miller's Anesthesia, 10e, p. 3272; Barash Clinical Anesthesia, 9e, p. 1615
6. Factors Affecting the ED95 Value (1 mark)
The ED95 is not a fixed number - it changes under different conditions:
| Factor | Effect on ED95 |
|---|
| Volatile anesthetic agents (sevoflurane, isoflurane, desflurane) | Decrease ED95 by 20-50% (potentiate NMBDs) - so a lower dose achieves the same effect |
| Nitrous oxide | Minor potentiation |
| Hypothermia | Potentiates NMBDs (decreased metabolism, prolonged duration) |
| Acid-base status | Respiratory acidosis potentiates; alkalosis antagonizes |
| Hypermagnesaemia | Potentiates block |
| Aminoglycoside antibiotics | Potentiate block |
| Myasthenia gravis | Extreme sensitivity - ED95 much lower for NDNMBDs |
| Burns, denervation (>24h) | Resistance to NMBDs (increased ACh receptors) |
Clinically: during volatile anesthesia, the intubating dose may be reduced by ~40% relative to doses used under N2O/O2/opioid anesthesia.
Miller's Anesthesia, 10e, p. 3265; Barash Clinical Anesthesia, 9e, p. 1615
7. Interpatient Variability (1 mark)
ED95 represents the median population response, but individual variation is enormous and clinically important:
- In a classic study (Katz, 1967), 0.1 mg/kg curare caused zero twitch depression in 6% of patients yet complete abolition in 7% - the same dose!
- Duration of action at equipotent doses is equally unpredictable
- Age, sex, body build, and ASA status cannot predict individual response to a given dose
- This variability is why quantitative neuromuscular monitoring (TOF ratio) is essential and cannot be replaced by clinical assessment or time
Barash Clinical Anesthesia, 9e, p. 1606
Summary Table
| Concept | Key Point |
|---|
| Definition | Median dose causing 95% twitch depression in 50% of patients |
| Standard intubating dose | 2× ED95 |
| RSI dose (rocuronium) | 4× ED95 (1.2 mg/kg) |
| Low ED95 | High potency |
| High ED95 | Low potency, but faster onset |
| Volatile agents | Reduce ED95 by ~40% |
| Monitoring | Essential due to wide interpatient variation |
Sources: Barash, Cullen & Stoelting's Clinical Anesthesia 9e (pp. 1597-1615); Miller's Anesthesia 10e (pp. 3229-3275)